Vicore Pharma Holding AB (publ) (STO:VICO)

Sweden flag Sweden · Delayed Price · Currency is SEK
7.94
+0.32 (4.20%)
May 9, 2025, 5:29 PM CET
-58.99%
Market Cap 1.86B
Revenue (ttm) 6.00M
Net Income (ttm) -311.88M
Shares Out 234.58M
EPS (ttm) -1.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 246,597
Average Volume 433,485
Open 7.65
Previous Close 7.62
Day's Range 7.62 - 8.01
52-Week Range 6.09 - 24.10
Beta 0.42
RSI 57.60
Earnings Date May 6, 2025

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Pha... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 29
Stock Exchange Nasdaq Stockholm
Ticker Symbol VICO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.